Apogee Therapeutics, Inc.
APGE
Peringkat dalam Saham
#2357
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Harga Saham
$135.07
Terakhir disinkronkan: 2026-09-04
Kapitalisasi Pasar
$8.36B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
137.21%
Negara
US
Perdagangan Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
EPS untuk Apogee Therapeutics, Inc. (APGE)
EPS per June 2026 TTM: $-4.34
Menurut laporan keuangan terbaru dan harga saham Apogee Therapeutics, Inc., EPS perusahaan saat ini (TTM) adalah $-4.34. Pada akhir 2023, perusahaan memiliki EPS sebesar $-1.66 peningkatan dibandingkan EPS tahun 2022 sebesar $-0.79.
Riwayat EPS untuk Apogee Therapeutics, Inc. dari 2022 hingga 2026
EPS di akhir setiap tahun
| Tahun | EPS | Mengubah |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS untuk perusahaan sejenis atau pesaing
| Perusahaan | EPS | Perbedaan EPS | Negara |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
